Our Company

Daniel A. Moros, M.D.

Dr. Moros is associate clinical professor of neurology at Icahn School of Medicine at Mount Sinai in New York City. His specialization is in movement disorders and behavioral neurology. He has spent many years in the pharmaceutical industry as vice chairman and medical director of Taro Pharmaceutical Co. Ltd. with responsibilities for generic and new drug development and regulatory affairs. In addition to numerous publications in medical ethics and the philosophy of medicine, for the last two decades, Dr. Moros has co-taught a graduate course in medical ethics at the City University of New York and Icahn School of Medicine.

Timothy Wiemken, Ph.D.

Dr. Wiemken is an Associate Professor in the Saint Louis University Center for Health Outcomes Research. He previously served as Associate Professor at the University of Louisville School of Public Health and Information Sciences, Department of Epidemiology and Population Health and as Assistant Professor in the Division of Infectious Diseases. He earned his doctorate in Public Health from the University of Louisville, a Master’s Degree in Epidemiology from Saint Louis University, and has a Bachelor’s Degree in microbiology from Southern Illinois University. He was previously an infection preventionist at the University of Louisville Hospital, has been certified in infection prevention since 2008, and is a fellow of the Association for Professionals in Infection Control and Epidemiology (APIC). He is active with APIC and the Society for Healthcare Epidemiology of America (SHEA), serving on many national committees. Dr. Wiemken has authored and co-authored numerous guidelines and book chapters on infectious diseases and infection prevention, and over 125 peer-reviewed journal articles related to infectious disease epidemiology. His research interests include pneumonia, influenza, emerging respiratory pathogens, quality and patient safety, healthcare-associated infections, and machine learning/artificial intelligence in healthcare.

Ronald Wysocki Jr., Ph.D.

Dr. Wysocki serves as program director of chemistry and biochemistry at The Ohio State University and was the director of the Chemical Synthesis Facility in the Department of Chemistry at the University of Arizona. Formerly, he was chief scientist at Pharos Pharmaceuticals Inc. in Green Valley, Arizona; the senior chemist at Discovery Therapeutics Inc. in Richmond, Virginia; and the scientist and group leader for Whitby Research Inc. in Richmond, Virginia. Dr. Wysocki’s research areas include organic thin films, transmembrane proteins and various aspects of spectroscopy. He holds several U.S. patents in his area of research.

Keith Tucker

Chairman of the Board

Keith is currently the director and chairman of Century Bridge Capital, a real estate investment firm with offices in Dallas, Texas, and Beijing, China. He served as chairman and CEO of Waddell & Reed Financial Inc., a publicly held mutual fund complex (NYSE: WDR), bringing the firm’s assets under his management from $5 billion to more than $40 billion. Prior to this, Keith served as vice chairman of the board of Torchmark Corporation, a publicly held insurance, financial services and real estate development company (NYSE: TMK) and as a partner with KPMG Peat Marwick.

Michael Ruley

Chief Executive Officer

Michael Ruley brings 30 years of expertise in business growth models as well as financial and tactical market positioning to advance the health mission of the company. Before joining Allied BioScience, Michael spent his career as a leader in the telecom industry. He has served as CEO of Airband Communications, Sparkplug Communications and Hawaiian Telcom. He also held posts as president and CEO of NextiraOne and several senior positions at XO Communications and Teleport Communications Group, and he currently serves as a board member of Tissue Genesis. Michael holds a Bachelor of Science in Business Administration and Management from the University of Kansas. Serving as a Board Member and CEO of three different North American-based companies, his expertise lies in quickly summing up a business – its strategy, model, financials, technology and competitive position – then outlining the right methods and building the right teams to accelerate top and bottom-line success. With a well-rounded blend of operating, financial, sales and marketing skills, Michael has successfully helped both private and publicly held entities strengthen and grow their valuations..

Henry A. Crumpton

Ambassador Henry A. Crumpton is the co-Chairman and co-CEO of Martin+Crumpton Group (M+CG) LLC, a global strategy and business development firm. He is also a partner in AIM13|CVP, a venture capital company based in New York. He previously served on the advisory boards of AECOM, DC Capital Partners, and The Coca Cola Company. In addition to Allied BioScience, he currently is on the advisory board of Stone Canyon Industries and he is a director of NavSight Inc.  

A 24-year veteran of the CIA’s Clandestine Service, he is the recipient of the Distinguished Intelligence Medal — the CIA’s highest award for achievement. In 2005 President George W. Bush appointed him Ambassador-at-Large and US Coordinator for Counterterrorism. Ambassador Crumpton graduated from of the University of New Mexico and Johns Hopkins School of Advanced International Studies, with honors. He is the author of The New York Times bestseller, The Art of Intelligence.

Vanessa Kerzner

Vanessa was in the hospitality industry for over a decade where she was an owner and board member of Kerzner International, a private company that built the Atlantis and One & Only hotels.  She is a graduate from Stanford University and INSEAD (France) and was a former consultant at Bain & Company in San Francisco and London.  During that time, she worked in M&A strategy and hospital cost reduction.  In addition to Allied BioScience, Vanessa currently serves on the board for a number of non-profit health care and education organizations, including Steadman Philippon Research Institute, Choate Rosemary Hall, a private high school in Connecticut, and the Butch Kerzner Memorial Trust Fund at the University of Johannesburg’s School of Tourism and Hospitality.

Daniel Moros, M.D.

Dr. Moros serves ABS as vice-chairman of scientific affairs. He is associate clinical professor of neurology at Icahn School of Medicine at Mount Sinai in New York City. His specialization is in movement disorders and behavioral neurology. He has spent many years in the pharmaceutical industry as vice chairman and medical director of Taro Pharmaceutical Co., Ltd. with responsibilities for generic and new drug development and regulatory affairs. In addition to being published in numerous publications in medical ethics and the philosophy of medicine, Dr. Moros has co-taught a graduate course in medical ethics at the City University of New York and Icahn School of Medicine for the last two decades.

Mohammed “Rab” Shanableh

With a career spanning 25 years in technology, Rab has held executive positions in Operations, Development and Systems Engineering leading divisions that have pioneered the way for the delivery of Mobile Packet Network. As co-founder and VP of Global Operations at Affirmed Networks (recently acquired by Microsoft), he shared in the coveted honor and success of Affirmed Networks being named a member of the prestigious Global Unicorn Club, an exclusive award recognizing outstanding current private companies valued at $1B+. He is presently the Managing Partner of Lydia Partners Venture Fund and the Co‑founder and CEO of OxeFit, a robotics tech company that focuses on robust strength training and human performance.